The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1).
Guo CJ, Leung PSC, Zhang W, Ma X, Gershwin ME.
Autoimmun Rev. 2018 Jan;17(1):78-85. doi: 10.1016/j.autrev.2017.11.012. Epub 2017 Nov 4.
Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I.
Oftedal BE, Marthinussen MC, Erichsen MM, Tveitarås MK, Kjellesvik-Kristiansen A, Hammenfors D, Jonsson MV, Kisand K, Jonsson R, Wolff ASB.
Autoimmunity. 2017 Jun;50(4):211-222. doi: 10.1080/08916934.2017.1344972. Epub 2017 Jul 7.
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.
Zhao Z, Wang X, Bao XQ, Ning J, Shang M, Zhang D.
Cancer Immunol Immunother. 2021 Jun;70(6):1527-1540. doi: 10.1007/s00262-020-02699-1. Epub 2020 Nov 16.
Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen.
Alimohammadi M, Björklund P, Hallgren A, Pöntynen N, Szinnai G, Shikama N, Keller MP, Ekwall O, Kinkel SA, Husebye ES, Gustafsson J, Rorsman F, Peltonen L, Betterle C, Perheentupa J, Akerström G, Westin G, Scott HS, Holländer GA, Kämpe O.
N Engl J Med. 2008 Mar 6;358(10):1018-28. doi: 10.1056/NEJMoa0706487.
The IVIG treatment response in autoimmune polyendocrine syndromes type 2 with anti-GAD65 antibody-associated stiff person syndrome: a case report and literature review.
Yang Y, Jiang H, Yang W, Wang H, Wang M, Li X, Huang P, Fang S, Hao W, Yang Y, Zhao F, He W.
Front Immunol. 2025 Jan 7;15:1471115. doi: 10.3389/fimmu.2024.1471115. eCollection 2024.
Autoimmune polyendocrine syndrome type 2 in children: a case report and literature review.
Liu Y, Wang F, Zhang L, Zhang H, Zhu Y.
BMC Pediatr. 2025 May 2;25(1):351. doi: 10.1186/s12887-025-05697-3.
Introduction: Autoimmune polyendocrine syndrome type 1 (APS-1): a rare monogenic disorder as a model to improve understanding of tolerance and autoimmunity.
Kämpe O.
J Intern Med. 2009 May;265(5):511-3. doi: 10.1111/j.1365-2796.2009.02094.x.
Autoimmune polyglandular syndrome type 2: A case report.
Bakkour A, Zakkor MD, Taha Khairy L, Horo R, Mohammed Sharif Ahmed E, Alhussein H.
Ann Med Surg (Lond). 2022 May 16;78:103742. doi: 10.1016/j.amsu.2022.103742. eCollection 2022 Jun.
Shock: A possible presenting manifestation of autoimmune polyendocrine syndrome type II.
Banzal S, Singhai A.
Indian J Crit Care Med. 2014 May;18(5):326-7. doi: 10.4103/0972-5229.132507.
Psoriasis in autoimmune polyendocrine syndrome type I: a possible complication or a non-endocrine minor component?
Poojary SA, Lodha N, Gupta N.
Indian J Dermatol Venereol Leprol. 2015 Mar-Apr;81(2):166-9. doi: 10.4103/0378-6323.152285.
